



A Double Dose!

Your trusted companions for nonprescription therapeutics

PATIENT SELF-CARE
 Helping Your Patients Make Therapeutic Choices
 Second Edition

COMPENDIUM OF SELF-CARE PRODUCTS
 The Canadian Reference for Nonprescription Products
 Second Edition



\$199.00*

\$99.00*

COMPLETELY REVISED AVAILABLE AUGUST 2010

Required texts for pharmacy reference libraries**

**BUNDLE AND SAVE \$48
 ORDER BY JUNE 30, 2010**

www.pharmacists.ca/products

Enter promo code: PHX05-FAX

or call 1-800-917-9489 x300

*Does not include shipping and taxes.
 CPhA members save 20% off retail price.
 **In select provinces



Product Information du Produit

SEPRACOR PHARMACEUTICALS, INC. WILL DISCONTINUE THE SALE OF ADVICOR 1000/40 (DIN # 02293501).

If you have any questions related to this announcement please contact Sepracor Customer Service at 905-363-0205. Thank you for your continued support of Sepracor Pharmaceuticals, Inc. products.

SMALLEST DIABETES PEN NEEDLE EVER

THE NEW BD ULTRA-FINE™ 4 MM 32G NANO PEN NEEDLE

BD is pleased to introduce the smallest pen needle for diabetes injections ever. The **BD Ultra-Fine™ 4 mm 32G Nano** is clinically proven safe and effective for patients of all sizes.* Designed for an improved injection experience, patients preferred the 4 mm 32G Nano for comfort and found it less intimidating than longer needles.† The BD Ultra-Fine™ 4 mm 32G Nano easily reaches the subcutaneous tissue layer for effective delivery of insulin and reduces the risk of intramuscular injections. The 4 mm 32G Nano offers universal fit with all diabetes pens in Canada.‡

The NEW BD Ultra-Fine™ 4 mm 32G Nano Pen Needles will be available as of Monday, May 3, 2010. **For more information and to place an order, please contact your Diabetes Care Consultant.**



*Tested in adults with BMI 20-49 kg/m².

†Compared with 5 mm and 8 mm pen needles; BD, Data on file.

‡BD, Data on file. BD, BD logo and BD Ultra-Fine™ are registered trademarks of Becton, Dickinson and Company ©2010 BD.

Formulary
Update

LEO PHARMA INC. IS PLEASED TO ANNOUNCE THAT XAMIOL® (calcipotriol/betamethasone dipropionate) GEL NOW LISTED ON THE:

Newfoundland and Labrador Prescription Drug Program under the special authorization program, for "patients who have failed a trial with a topical steroid alone, and who have failed a trial with a topical steroid and calcipotriol together."

Name	Xamiol®
Form	gel
Strength	50 µg/g calcipotriol (as monohydrate), 0.5 mg/g betamethasone (as dipropionate)
Indicated Dosing	For the topical treatment of moderate to severe scalp psoriasis for up to 4 weeks.
Format	60 g bottle
DIN	02319012

Product monograph available upon request. For medical information please call 1-800-263-4218 or email medical-info.ca@leo-pharma.com



© Registered trademark of LEO Pharma A/S used under license and distributed by LEO Pharma Inc., Thornhill, ON

**Visit us at
www.ipharmadirect.com**